Defining the Genetic Etiology of Alzheimer's Disease in the Faroe Islands

Launched by FAROESE HOSPITAL SYSTEM · Aug 9, 2018

Keywords

ClinConnect Summary

This clinical trial, titled "Defining the Genetic Etiology of Alzheimer's Disease in the Faroe Islands," is focused on understanding the genetic and environmental factors that may contribute to Alzheimer's disease (AD). Researchers are studying the Faroese population, which has a unique genetic background and a strong community connection, to identify what might increase the risk of developing AD. The study involves enrolling individuals with Alzheimer's, their close family members, and matched control subjects without dementia, which helps create a clearer picture of how genes and environment play a role in this disease.

To participate, individuals should be diagnosed with dementia (for cases), or be age and gender-matched controls without dementia. Close relatives of people with dementia are also encouraged to join the study. Participants can expect to take part in detailed genealogical research and contribute to important findings that could lead to better understanding and treatment of Alzheimer's disease. This trial is currently recruiting participants and aims to leverage the unique characteristics of the Faroese population to make significant advancements in Alzheimer's research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of dementia (cases)
• • Age and gender matched to cases (controls)
• • Close relatives to an individual with dementia (family members)
• Exclusion Criteria:
• • No exclusion criteria (cases and family members)
• • Sign of dementia assessed by MMSE (controls)